Cuba tests drug that relieves painful aftereffects of Chikungunya virus
Cuba is conducting the second phase of clinical trials for Jusvinza, a locally developed drug that relieves painful symptoms and inflammation in patients recovering from the chikungunya virus
The Cuban drug Jusvinza is advancing to the second phase of clinical trials, demonstrating its effectiveness in relieving pain and inflammation in secondary joints in patients recovering from the chikungunya virus.
This was reported by Julio Baldomero, director of Clinical Research at the Center for Genetic Engineering and Biotechnology (CIGB).
According to the specialist, “the final data confirmed the hypothesis put forward by the researchers.” In this regard, Baldomero stated that they managed to resolve the “painful and inflammatory symptoms of the joints caused by this virus, which is transmitted by mosquitoes and has affected tropical regions of the world.”
What is Jusvinza?
The medication is essentially an innovative therapeutic product developed at the CIGB (Center for Genetic Engineering and Biotechnology). The active ingredient “is a peptide originally designed to treat rheumatoid arthritis” that was incorporated into the Cuban national protocol during the COVID-19 pandemic for use in “severely ill patients, helping to reduce mortality on the Caribbean island before the arrival of vaccines.”
Clinical trials with promising results
In early December 2025, two clinical trials began to verify the therapeutic effect and safety of Jusvinza in these types of patients.
“The first study was conducted at the Diez de Octubre Clinical Surgical Teaching Hospital in Havana and included 174 people in the post-acute stage; while the second was carried out at the Faustino Pérez Provincial Clinical Surgical Teaching Hospital in the western province of Matanzas, with 120 individuals in the chronic stage of the disease.”
The conclusions of both studies indicate that 70 % of the patients achieved the expected results. Specialists demonstrated the efficacy and safety of the product. Furthermore, it was found that “it is not only effective in relieving joint symptoms, but its effects are long-lasting, preventing patients from developing the chronic form of the disease.”
M.Pino
Source: xinhuanet
(Reference image source: Louis Reed on Unsplash)
Follow our news on Google! For current, interesting, and accurate information, click here to see all the content on Bitfinance.news. You can also find us on X/Twitter and Instagram
